7.4.4.4. treatment hereditary rcc. 7.4.4.4.1.von-hippel-lindau-disease-associated rcc patients vhl disease often develop rcc tumours cysts organs including adrenal glands, cns, retinal haemangioblastomas, pancreas, commonly undergo several surgical resections lifetime. vhl disease, belzutifan, hif-2Î± inhibitor, approved us food drug administration (fda, august 2021) treatment ccrcc neoplasms associated vhl treatment tumours require immediate surgery. approval based results phase ii, open-label, single-arm trial 61 patients tumours larger 3 cm . belzutifan induced partial responses rcc orr 49%, disease control rate 98.4% 21.8 months treatment. patients pancreatic lesions orr 77%, cns haemangioblastoma 30% response rate. total, 33% patients reported > grade iii adverse events, seven patients (11.5%) discontinued treatment. treatment pazopanib vhl 52% continued treatment 24 weeks . longer follow-up 37.8 months, orr rcc increased 64%, median time response 11.1 months (range, 2.7 30.5). median duration response per kaplan-meier estimate reached (range, 5.4+ 35.8+ months). thirty-four 39 patients confirmed response (87%) remain response data cut-off date (september 2022) . favourable efficacy results relatively low-grade side effects, belzutifan seems valuable contribution treatment patients vhl disease. ema yet considered belzutifan approval vhl disease.